Advances in ILDs and Orphan Lung Diseases

June 23, 2012 in Essen, Germany. For program and registration details see our Meetings section.  

WASOG North American Conference

This conference will be held in Cleveland, USA - 4-6 October, 2012. Go directly to conference website ►

6th International WASOG Conference

This Conference will be held in Paris, La Sorbonne - June 6th - 7th, 2013. View announcement ► 

Call for Case Reports

The WASOG website offers a unique opportunity to publish case reports online (open access)! Don't hesitate and share your findings with the rest of the community. Read more ►

WASOGBAL 2014 Announced!

WASOGBAL2014 will be held in Izmir, Turky. View our flyer ►

WASOGBAL 2011 - View Video's online!

The combined 10th WASOG Meeting and the 12th International Conference on BAL was a great success. We had 275 attendees from more than 30 countries. Please visit the website for the abstracts, e-posters, congress photos & videos with some complete lectures and more details.

WASOG on LinkedIn

Follow us and get connected to WASOG on LinkedIn!

Sarcoidosis and other ild around the world

To inform you about sarcoidosis and other ild in different countries we ask(ed) colleagues to summarize the prevalence, the research and important websites, etc. This topic has been added to the WASOG site. Read more ►

Newsletter

Keep up to date with the WASOG Newsletter - subscribe


New Literature

Therapy for sarcoidosis: evidence-based recommendations, by Baughman RP, Nunes H. Treatment of sarcoidosis depends on the level of symptoms and the duration of disease. Based on current evidence, a specific plan for therapy can usually be developed. While there is no single therapy for all patients, a stepwise approach seems reasonable for most cases. It should be noted that not all patients respond to therapy. In recent reports, it was found that the mortality from sarcoidosis has remained the same or has risen over the past 20 years, despite the increasing use of anti-inflammatory drugs. There is some controversy about whether the mortality associated with sarcoidosis is as high as the 5% noted in referral centers, or the less than 1% noted at primary centers. However, it is clear that there is a subset of severe chronic patients. The rate of these chronic patients appears to be similar at sarcoidosis clinics around the world. Read more ►

Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease, by Sprunger DB, et al. Recent epidemiological studies have suggested an increased risk of venous thromboembolism (VTE) in lung fibrosis. Large-scale epidemiological data regarding the risk of VTE in pulmonary fibrosis-associated mortality have not been published. Using data from the National Center for Health Statistics from 1988–2007, we determined the risk of VTE in decedents with pulmonary fibrosis in the USA. Decedents with pulmonary fibrosis had a significantly greater risk of VTE. Those with VTE and pulmonary fibrosis died at a younger age than those with pulmonary fibrosis alone. These data suggest a link between a pro-fibrotic and a pro-coagulant state. Read more ►

Delayed Access and Survival in Idiopathic Pulmonary Fibrosis, by Lamas DJ, et al. Delays in accessing care occur frequently among patients with idiopathic pulmonary fibrosis (IPF). The harms of delayed access to an interstitial lung disease (ILD) center have not been previously examined. Delayed access to a tertiary care center is associated with a higher risk of death in IPF independent of disease severity. Early referral to an ILD center should be considered for those with suspected or known interstitial lung disease. Read more ►

Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis, by de Kleijn WP, et al. The usefulness of any questionnaire in clinical management and research trials depends on its ability to indicate a likelihood of treatment success during follow-up. The Minimal Clinically Important Difference (MCID) reflects a clinically relevant change score. The aim of this study was to estimate the MCID for the Fatigue Assessment Scale (FAS) in patients with sarcoidosis. Outpatients (n = 321) of the ild care team of the Dept. of Respiratory Medicine of the Maastricht University Medical Centre, The Netherlands, participated in this prospective follow-up study. Based on the anchor-based and distribution-based methods, the MCID is a 4-point difference on the FAS. Read more ►
 

WASOG - World Association of Sarcoidosis and Other Granulomatous Disorders - WASOG, join wasog, wasog congresses, wasog meetings, wasog journal, wasog members, wasog history, wasog mission, wasog goals, wasog case report, wasog publications, wasog key papers